Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SAR292833 · 1 trial · 1 indication
The average daily pain intensity is the mean of the last consecutive 7 days.
| Arm | Type | Description |
|---|---|---|
| SAR292833 dose level 1 | EXPERIMENTAL | Dose level 1 twice daily immediately after breakfast/dinner |
| SAR292833 dose level 2 | EXPERIMENTAL | Dose level 2 twice daily immediately after breakfast/dinner |
| Placebo | PLACEBO_COMPARATOR | Placebo (for SAR292833) twice daily immediately after breakfast/dinner |
| Name | Type | Description |
|---|---|---|
| SAR292833 | DRUG | Pharmaceutical form: capsule Route of administration: oral |
| placebo | DRUG | Pharmaceutical form:capsule Route of administration: oral |
Inclusion criteria: -The study will include adult patients of either gender, 18 - 85 of age, who have signed the informed consent form, and presenting with chronic peripheral neuropathic pain associated with: diabetic polyneuropathy, post-herpetic neuralgia. * The neuropathic pain must have a dist...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 1 | PHASE2 | LY3016859 ISA, LY3556050 ISA, LY3526318 ISA, LY3857210 ISA |
| Dogwood Therapeutics Inc | DWTX | 1 | PHASE2 | Halneuron |
| Sangamo Therapeutics, Inc. | SGMO | 1 | PHASE1 | ST-503 |
| Boston Scientific Corporation | BSX | 1 | N/A | Undisclosed |
| Collegium Pharmaceutical, Inc. | COLL | 1 | N/A | Undisclosed |
SAR292833 is an investigational small molecule being developed for the treatment of chronic peripheral neuropathic pain. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
SAR292833 is being developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker SNY. The drug is currently in Phase 2 clinical trials for neuropathic pain.
SAR292833 is in Phase 2 clinical development. It has completed one Phase 2 trial, which was a randomized, double-blind, placebo-controlled study. The drug is investigational and has not been approved for commercial use.
SAR292833 has one completed clinical trial, NCT01463397, which evaluated its efficacy and safety over 4 weeks in patients with chronic peripheral neuropathic pain. The trial enrolled 191 participants across multiple countries, including the United States, Czechia, Hungary, Poland, Russia, Slovakia, and Ukraine.
SAR292833 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for neuropathic pain. The completed Phase 2 trial was a randomized, double-blind, placebo-controlled study, but the drug has not yet received regulatory approval.